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Abstract
Background: Reduced chemosensitivity of solid cancer cells represents a pivotal obstacle in clinical oncology. Hence, the
molecular characterization of pathways regulating chemosensitivity is a central prerequisite to improve cancer therapy. The
hypoxia-inducible factor HIF-1a has been linked to chemosensitivity while the underlying molecular mechanisms remain
largely elusive. Therefore, we comprehensively analysed HIF-1a’s role in determining chemosensitivity focussing on
responsible molecular pathways.
Methodology and Principal Findings: RNA interference was applied to inactivate HIF-1a or p53 in the human gastric cancer
cell lines AGS and MKN28. The chemotherapeutic agents 5-fluorouracil and cisplatin were used and chemosensitivity was
assessed by cell proliferation assays as well as determination of cell cycle distribution and apoptosis. Expression of p53 and
p53 target proteins was analyzed by western blot. NF-kB activity was characterized by means of electrophoretic mobility
shift assay. Inactivation of HIF-1a in gastric cancer cells resulted in robust elevation of chemosensitivity. Accordingly, HIF-1a-
competent cells displayed a significant reduction of chemotherapy-induced senescence and apoptosis. Remarkably, this
phenotype was completely absent in p53 mutant cells while inactivation of p53 per se did not affect chemosensitivity. HIF-
1a markedly suppressed chemotherapy-induced activation of p53 and p21 as well as the retinoblastoma protein, eventually
resulting in cell cycle arrest. Reduced formation of reactive oxygen species in HIF-1a-competent cells was identified as the
molecular mechanism of HIF-1a-mediated inhibition of p53. Furthermore, loss of HIF-1a abrogated, in a p53-dependent
manner, chemotherapy-induced DNA-binding of NF-kB and expression of anti-apoptotic NF-kB target genes. Accordingly,
reconstitution of the NF-kB subunit p65 reversed the increased chemosensitivity of HIF-1a-deficient cells.
Conclusion and Significance: In summary, we identified HIF-1a as a potent regulator of p53 and NF-kB activity under
conditions of genotoxic stress. We conclude that p53 mutations in human tumors hold the potential to confound the
efficacy of HIF-1-inhibitors in cancer therapy.
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Introduction
Intrinsic and acquired drug resistance are the primary causes for
limited efficacy of chemotherapy in the majority of gastrointestinal
malignancies, including gastric cancer [1,2]. Drug resistance
represents a complex and multifactorial phenomenon related to
tumor microenvironment, e.g. hypoxia, acidosis and inflammation
as well as the neoplastic cell itself [3]. Cellular resistance may be
inherent to the specific genetic background of the tumor cell or
result from mutations and epigenetic alterations after antiprolif-
erative therapy [4,5].
The transcription factor hypoxia-inducible factor 1 (HIF-1)
constitutes a pivotal regulator of cellular adaptation to hypoxia
and has been implicated in drug resistance [6–8]. The HIF-1
protein is a heterodimer composed of a constitutively expressed b-
subunit (ARNT (aryl hydrocarbon receptor nuclear translocator))
and a hypoxia-inducible a-subunit [9]. Under normoxic condi-
tions, HIF-1a activity can be induced by various growth factors,
cytokines, activated oncogenes or loss-of-function mutated tumor
suppressor genes [10]. HIF-1a is centrally involved in multiple
aspects of tumorigenesis including tumor cell proliferation,
angiogenesis, metastasis, as well as the response to chemo- and
radiotherapy [11]. HIF-1a is overexpressed in a vast number of
solid tumors, and tumoral HIF-1a expression is often associated
with poor prognosis [12–15]. Furthermore, inhibition of HIF-1a
by means of RNA interference or pharmacological compounds has
proven antitumoral efficacy in various murine cancer models [16].
A contribution of HIF-1a to chemoresistance of neoplastic cells
has been observed in a wide spectrum of solid tumors, including
gastric cancer [6–8,17–20]. However, the underlying molecular
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12038
Figure 1. HIF-1a mediates resistance towards the chemotherapeutic agent 5-FU in AGS cells. (A) Proliferation of AGS KD and SCR cells
24 h after treatment with increasing concentrations of 5-FU under normoxic conditions. Cell numbers are shown as percent of untreated cells
(*, P,0.05; **, P,0.01). (B) AGS wild-type cells were transfected with HIF-1a expression vector (pcDNA HIF-1a) or empty vector (pcDNA 3.1) and
treated with 5-FU 24 h post transfection. Cell numbers were determined 24 h after treatment with 5-FU, and are shown as percent of untreated
control cells (**, P,0.01). (C) AGS wild-type cells were co-transfected with either pcDNA HIF-1a or pcDNA 3.1 plus HRE-Luciferase reporter (pHRE-Luc)
and Renilla reporter (phRL-null) as internal control. Cells were harvested 48 h post transfection. HRE luciferase activity, normalised for Renilla luciferase
activity, was expressed relative to that of control transfected cells (***, P,0.001).
doi:10.1371/journal.pone.0012038.g001
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Figure 2. HIF-1amediates resistance towards 5-FU by blocking p53-dependent G1 arrest and apoptosis. (A) AGS KD and SCR cells were
treated for 24 h with 10 mg/ml 5-FU, and cell cycle distribution was determined by FACS analysis (**, P,0.01). (B) Chemotherapy-induced senescence
was quantified in AGS KD and SCR cells 4 days after treatment with 5-FU by measurement of SA-b-Gal activity (**, P,0.01). (C) AGS KD and SCR cells
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mechanisms as well as the role of HIF-1a for drug resistance under
normoxic conditions remain largely elusive [8,18,21]. Here, we
identify suppression of p53 and promotion of nuclear factor kB
(NF-kB) activity as central mechanisms for HIF-1a‘s sensitivity-
determining role against 5-fluorouracil (5-FU) and cisplatin in
human gastric cancer cells.
Results
HIF-1a determines sensitivity of gastric cancer cells
towards the chemotherapeutic agents 5-FU and cisplatin
Functional inactivation of HIF-1a was achieved by lentiviral
transduction of AGS and MKN28 cells with small interfering
RNA (siRNA) specifically targeting HIF-1a. This experimental
approach yielded a highly efficient knockdown demonstrated by a
near complete failure of transduced cells to induce HIF-1a protein
in response to hypoxia as published previously [22]. To evaluate
the importance of HIF-1a for the sensitivity of human gastric
cancer cells towards established chemotherapeutic agents, we
compared the effects of 5-FU and cisplatin in HIF-1a-competent
(scrambled, ‘‘SCR’’) and HIF-1a-deficient (knockdown, ‘‘KD’’)
AGS cells. Functional inactivation of HIF-1a shifted the dose
dependency of growth inhibition towards lower drug concentra-
tions (Figure 1A and Figure S1), suggesting that HIF-1a is capable
to reduce chemotherapy susceptibility of gastric cancer cells under
normoxic conditions. In line with previous reports [6–8,17,18],
exposure to hypoxia increased resistance to 5-FU in AGS cells,
however inactivation of HIF-1a resulted in robust elevation of
chemosensitivity under hypoxic conditions (Figure S2). In a
complementary approach, we studied the consequences of
overexpressing HIF-1a (pcDNA HIF-1a) for the chemosensitivity
of AGS cells. AGS cells overexpressing HIF-1a were considerably
more resistant to treatment with 5-FU (Figure 1B). Stable HIF-1a
expression was confirmed by HRE (hypoxia responsive element)
luciferase reporter assay (Figure 1C). These results strongly suggest
that HIF-1a limits the cytotoxic action of 5-FU and cisplatin in
human gastric cancer cells and that inactivation of HIF-1a may
have beneficial effects on chemosensitivity.
HIF-1a limits chemotherapy-induced cell cycle arrest and
apoptosis via suppression of p53
We started a characterization of the observed growth inhibition
by analyzing cell cycle distribution patterns after chemotherapy.
G1-synchronized, serum-starved AGS cells were released from
G0/G1 phase by addition of serum and cell cycle profiles were
determined following the addition of 5-FU. Released cultures of
untreated AGS readily progressed through G1 into S and G2/M
phases [22], whereas 5-FU-treated cells remained in G1 phase (not
shown). Interestingly, the 5-FU-dependent retention of cells in G1
phase was greatly augmented in AGS KD compared to AGS SCR
cells, consistent with G1 cell cycle arrest (Figure 2A). Irreversible
cell cycle arrest has emerged as an important mode of action of
antiproliferative agents and is characterized by cellular features of
senescence [7,23]. Accordingly, the fraction of senescent cells was
determined. Indeed, treatment with 5-FU led to a robust induction
of senescence in AGS cells. This response was significantly
enhanced in cells with concurrent loss of HIF-1a (Figure 2B).
Furthermore, induction of apoptosis was suggested by an increased
pre G1 fraction in DNA histograms of 5-FU-treated AGS KD cells
(not shown). Therefore, a quantitative analysis of the apoptotic cell
fraction was obtained based on the detection of cleaved caspase-3
(Figure 2C). Consistent with the data on cell cycle distribution, the
5-FU-induced apoptotic fraction was significantly increased in
HIF-1a-deficient AGS KD cells as compared to HIF-1a-
competent cells.
Chemotherapy-induced senescence and apoptosis both have
been intimately linked to the tumor suppressor p53. Thus, we
hypothesized that p53 might contribute to augmented cytotoxicity
of 5-FU upon loss of HIF-1a. After 5-FU treatment, p53 protein
gradually accumulated in AGS cells, an effect that was strikingly
enhanced in HIF-1a-deficient AGS cells (Figure 2D). This
stabilization of p53 was associated with increased levels of the
cyclin-dependent kinase (CDK) inhibitor p21, a well established
transcriptional target and downstream effector of p53 with
functions in cell cycle arrest, senescence induction and apoptosis
(Figure 2D). Again, HIF-1a-deficient AGS cells showed a
markedly stronger increase in p21 than HIF-1a-proficient AGS
cells. Strong induction of p21 is expected to inhibit the activity of
G1 cyclin/CDK complexes, resulting in hypophosphorylation of
retinoblastoma protein (pRb) and failure to induce S phase cyclins,
e.g. cyclin A. Indeed, both pRb hypophosphorylation and reduced
cyclin A levels were confirmed in 5-FU-treated AGS KD cells
and - to a lesser extent - also in AGS SCR cells (Figure 2D). These
changes corroborate the G1 phase retention observed in DNA
histograms and are consistent with the irreversible G1 arrest
observed in chemotherapy-induced senescence. Thus, the different
biological outcomes of 5-FU treatment in HIF-1a-deficient and –
proficient AGS cells arise from differential regulation of p53 and
its downstream target p21.
Inactivation of p53 blunts the role of HIF-1a for
chemosensitivity
To obtain experimental evidence for the proposed role of p53 in
HIF-1a-mediated regulation of chemosensitivity in AGS cells, we
functionally inactivated p53 by RNA interference using transient
transfection of anti-p53 siRNA (si p53), or a scrambled control
siRNA (si scr). P53 was efficiently knocked down, as indicated by
the failure of the transfected cells to induce the p53 effectors p21
and MDM2 in response to 5-FU treatment (Figure 3A).
Interestingly, AGS KD cells transfected with si p53 were
significantly less susceptible to growth inhibition by 5-FU than
AGS KD cells transfected with control siRNA (Figure 3B). In line
with these findings, G1 cell cycle retention and apoptosis of 5-FU-
treated AGS KD cells were reduced by p53 knockdown in
comparison to cells transfected with control siRNA (Figure 3D and
3E). In sharp contrast, chemosensitivity of HIF-1a-proficient AGS
cells was not influenced by inactivation of p53 (Figure 3C).
HIF-1a fails to affect chemosensitivity in p53 mutant cells
To confirm the HIF-1a-dependent regulation of 5-FU respon-
siveness and to further characterize the contribution of p53, we
examined a second human gastric cancer cell line (MKN28),
which carries a missense mutation in TP53 at codon 251.
Interestingly, deletion of HIF-1a in MKN28 cells failed to
enhance the growth inhibition after exposure to 5-FU
(Figure 4A). Similarly, 5-FU-induced G1 accumulation and
apoptosis of MKN28 cells were not affected by loss of HIF-1a
(Figure 4B and 4C). In line with these findings, the protein levels of
were treated for 48 h with 10 mg/ml 5-FU and apoptosis was quantitated based on detection of active caspase-3 using flow cytometry (**, P,0.01).
(D) Representative immunoblot analysis of p53, p21, CDK2, cyclin A and pRb protein levels in AGS KD and SCR cells treated with 10 mg/ml 5-FU for 6
and 24 h. Actin served as loading control. ppRb, phosphorylated pRb.
doi:10.1371/journal.pone.0012038.g002
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Figure 3. siRNA silencing of p53 reverses the chemosensitization of AGS KD cells. AGS cells were transfected with control siRNA (si scr) or
siRNA against p53 (si p53), and 10 mg/ml 5-FU was added 24 h post transfection. (A) Immunoblot analysis for p53, p21 and MDM2 in whole cell
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p53 and pRb remained unchanged in 5-FU-treated MKN28 cells
throughout the 24 h period, and p21 induction was absent
(Figure 4D). However, when p53 function was restored by
pretreatment with the chemical compound PRIMA-1 [24] HIF-
1a knockdown translated into a significantly enhanced 5-FU
cytotoxicity (Figure S3). Consistent with the established role of p53
in chemotherapy-induced cytotoxic/cytostatic effects, treatment
with PRIMA-1 per se slightly reduced the proliferation of MKN28
cells and significantly enhanced the efficacy of 5-FU in MKN28
cells (Figure S3).
NF-kB is an important mediator of HIF-1a’s role in
chemosensitivity
Activation of NF-kB is associated with protection from
chemotherapy-induced apoptosis and, conversely, inhibition of
NF-kB can enhance the efficacy of anti-neoplastic agents both in
vivo and in vitro [25–27]. Therefore, we determined NF-kB DNA-
binding activity in HIF-1a-deficient and –proficient AGS cells
after treatment with 5-FU by electrophoretic mobility shift assay
(EMSA). Treatment with 5-FU potently activated NF-kB DNA-
binding in AGS SCR cells, with peak levels occurring 6 h after
exposure to 5-FU (Figure 5A). Treatment with TNFa for 4 h
served as positive control for activation of NF-kB. Furthermore, a
supershift was induced by an anti-p65 antibody, confirming that 5-
FU induced NF-kB complexes contained the 65-kDa subunit
(p65). Loss of HIF-1a significantly inhibited activation of NF-kB in
response to 5-FU and TNFa (Figure 5A). Consistent with this
observation, 5-FU treatment also failed to induce the NF-kB target
genes cIAP1 and A20 in AGS KD cells, whereas they were readily
induced in AGS SCR cells (Figure 5B).
To address the functional significance of NF-kB for 5-FU-
induced growth inhibition, we overexpressed p65 (pcDNA p65) in
AGS KD cells. Transfection of pcDNA p65, but not the empty
control vector, resulted in a significant induction of p65 protein
and NF-kB transcriptional activity in AGS KD cells (Figure S4).
Of note, HIF-1a-deficient AGS KD cells overexpressing p65 were
considerable more resistant to 5-FU treatment compared to AGS
KD cells transfected with the control vector (Figure 5C), consistent
with an essential role of NF-kB in mediating chemoresistance
towards 5-FU in gastric cancer cells. Taken together, a concurrent
activation of p53 and inhibition of NF-kB in 5-FU-treated, HIF-
1a-deficient AGS cells was observed. To clarify, whether both
events are interdependent, we studied 5-FU-induced NF-kB
activation in MKN28 cells with mutant p53. Both 5-FU and
TNFa activated NF-kB DNA-binding in a time-dependent
manner, indicating p53-independent mechanisms of NF-kB
activation by 5-FU (Figure 5D). However, different from the
finding in AGS cells, this NF-kB activation in the p53 mutant cell
line was not blunted by HIF-1a inactivation. Thus, HIF-1a may
support chemotherapy-induced NF-kB activation by counteract-
ing p53-dependent inhibitory mechanisms.
Altered ROS formation is responsible for HIF-1a-induced
modification of p53 activity
To clarify the molecular mechanism underlying p53 superin-
duction in 5-FU-treated HIF-1a-deficient cells, we characterized
the role of reactive oxygen species (ROS). ROS constitute a
candidate link as (i) ROS are potent activators of p53 function and
considered key factors in the induction of p53 by various
chemotherapeutic agents [28], and (ii) HIF-1a can suppress
ROS generation by decreasing mitochondrial activity and
biogenesis [22,29,30]. Accordingly, AGS KD cells were pretreated
with the ROS-inhibitors diphenyleneiodonium chloride (DPI) or
apocynin. Both inhibitors conferred significant protection against
5-FU-induced growth inhibition in AGS KD cells (Figure 6A and
6B). Furthermore, DPI and apocynin almost completely prevented
the induction of p53 and its downstream target p21 in 5-FU-
treated cells (Figure 6C and 6D). These results suggest an
intersection of HIF-1a signalling with the p53-mediated response
to 5-FU at the level of ROS production. To establish a causal role
of HIF-1a for the redox potential of AGS cells after 5-FU
treatment, intracellular ROS levels were determined in AGS KD
and SCR cells by flow cytometry. We found that the intracellular
superoxide levels in 5-FU-treated AGS KD cells were 2.5-fold
higher than those in 5-FU-treated AGS SCR cells (Figure S5),
indicating that functional inactivation of HIF-1a in AGS cells
resulted in significant and functional elevation of intracellular
oxidative stress even under chemotherapeutic treatment.
Discussion
The transcription factor HIF-1a has been established
as important mediator of hypoxia-mediated chemoresistance
[6–8,17,18,20]. Here, we identify HIF-1a as a powerful determi-
nant of chemosensitivity in gastric cancer cells under normoxic
conditions. By applying a lentivirus-based siRNA system we show
significantly enhanced 5-FU and cisplatin toxicity in HIF-1a-
deficient gastric cancer cells. Available data on the role of HIF-1a
for the chemosensitivity of cancer cells under normoxic conditions
are conflicting. While HIF-1a-deficient fibrosarcoma cells
(HT1080) displayed significantly enhanced sensitivity towards
etoposide under ambient air, colon cancer (HCT116) and
hepatoma (Hepa-1) cells failed to do so [6]. Unruh et al. reported
enhanced susceptibility of HIF-1a-deficient murine embryonic
fibroblasts to carboplatin or etoposide under normoxic as well as
hypoxic conditions [8]. With respect to gastric cancer, enhanced
efficacy of 5-FU and vincristine was demonstrated under
normoxia in vitro [18]. Well in line with our results, both studies
concluded a pivotal role for HIF-1a in mediating chemoresistance
under normoxic conditions. Interestingly, a recent study from
Japan demonstrated lower efficacy of 5-FU-based chemotherapy
in HIF-1a-expressing human gastric adenocarcinomas, strength-
ening the perception of HIF-1 as a pivotal factor in the
determination of gastric cancer chemoresistance [31].
Control of cancer progression by chemotherapy relies at least in
part on induction of cellular senescence. Recently, loss of HIF-1a
was shown to cause premature senescence of immortalized murine
embryonic fibroblasts under normoxic conditions [32]. Our
current data suggests that HIF-1a similarly guards gastric cancer
cells against chemotherapy-induced senescence under normoxic
conditions. This constitutes the first report of elevated chemo-
therapy-induced senescence via functional inactivation of HIF-1a
in an established human cancer cell line. In HIF-1a-deficient cells,
we also observed improved apoptosis induction in response to 5-
FU. Previous studies reported a reactivation of the proapoptotic
factor Bid [6], or a change in the balance of pro- and antiapoptotic
extracts from AGS KD cells after 5-FU treatment. Actin served as loading control. (B and C) Cell numbers of si scr and si p53 transfected AGS cells was
determined 24 h after treatment with 5-FU. Results are shown as percent of untreated control cells (**, P,0.01). Cells in the G1 phase (D) and the
sub-G1 population (E) were evaluated from DNA histograms of AGS KD cells transfected with si p53 or si scr and treated for 24 h with 5-FU (*, P,0.05;
**, P,0.01).
doi:10.1371/journal.pone.0012038.g003
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Bcl-2 family members to account for increased apoptosis rates
following inactivation of HIF-1a in drug-treated gastric cancer
cells [18].
Our current study identifies a novel mechanism, whereby HIF-
1a counteracts both chemotherapy-induced senescence and
apoptosis: We present conclusive evidence for the capacity of
HIF-1a to suppress the induction of the tumor suppressor p53 in
response to 5-FU under normoxic conditions. P53 is a pivotal cell
fate determinant due to its role in regulating cell-cycle progression
and apoptosis in response to cellular stress and constitutes the most
commonly mutated gene in human cancers [33]. A wide variety of
chemotherapeutic agents were shown to stabilize p53 and,
conversely, loss of p53 constitutes a principle mechanism of
cancer resistance towards chemotherapy [33,34]. The interaction
of p53 and HIF-1a has been the subject of longstanding debates as
both positive and negative reports have been published [35].
However, the entire previously published work focussed on p53-
HIF-1a-interactions under hypoxic (or even anoxic) conditions.
To the best of our knowledge, our experiments for the first time
provide evidence for the suppression of p53 activity by HIF-1a
under normoxic conditions. As consequence of p53 upregulation
in HIF-1a-deficient cells, we observed changes in downstream
effectors that are linked to the irreversible cell cycle arrest
characteristic of senescence, e.g. p21 stabilization and hypopho-
sphorylation of pRb. Different from our observation, recent work
on chemoresistance towards etoposide in HIF-1a-deficient im-
mortalized murine embryonic fibroblasts did not observe an
induction of p21 [36]. Also, HIF-1a stabilized p21 and p27 as well
as led to hypophosphorylation of pRb during hypoxia-induced
growth arrest of immortalized murine embryonic fibroblasts and
primary splenic B-lymphocytes [37]. These contrasting results are
most likely explained by the investigated cell types: While Goda
et al. characterized a physiological response to hypoxia in non-
transformed cell types, we analyzed the response to severe DNA
damage in established cancer cell lines.
While p53 was repeatedly shown to counteract NF-kB
function [38,39], our current data indicate a role for the tumor
suppressor in the regulation of HIF-1a-dependent NF-kB
activation. Apart from p53, NF-kB has emerged as a second,
central determinant of resistance towards chemotherapeutic
agents [40]. Several different studies have established functional
links between NF-kB and HIF-1a, though they variably place
HIF-1a either upstream of NF-kB or vice versa. For instance,
hypoxia-induced stabilization of HIF-1a in smooth muscle cells
is under transcriptional control of NF-kB [41]. Similarly, results
obtained from conditional IKK-b knockout mice confirmed the
pivotal role of NF-kB in controlling basal and hypoxia-induced
expression of HIF-1a in vivo [42]. Conversely, gene expression of
the NF-kB subunit p65 was demonstrated to be controlled by
HIF-1a in the context of hypoxia-suppressed apoptosis of
neutrophils [43]. Our finding of markedly reduced NF-kB
activity in HIF-1a-deficient cells upon treatment with 5-FU
therefore is well in line with this latter report. Interestingly, we
also observed significantly reduced DNA binding of NF-kB
subunits in HIF-1a-deficient cells after stimulation with TNFa,
a well established inducer of NF-kB activity [44]. This raises the
pertinent question under which physiological and pathophysi-
ological conditions HIF-1a is able to regulate NF-kB activation.
HIF-1a and NF-kB share crucial importance for various
processes such as inflammation, microbial killing and tumori-
genesis. The exact molecular nature as well as the hierarchy of
their interaction is most likely cell- and context-dependent and
can not be generalized.
In the current study we were able to pinpoint ROS as an
intersection point of HIF-1a with the p53-mediated cellular
stress response to chemotherapy. Intracellular ROS are known
as potent inducers of p53 and participate in the activation of
p53 by chemotherapeutic drugs [45]. Mitochondria represent
the prime source of intracellular ROS [46], and HIF-1a likely
counteracts ROS production at the mitochondrial level via
multiple mechanisms including inhibition of mitochondrial
biogenesis and of pyruvate shuttling into the mitochondria,
reduction of mitochondrial activity due to enhanced utilization
of glycolysis and activation of mitochondrial autophagy
[29,30,47,48]. Previously, we established a functional link
between HIF-1a-controlled reduction of ROS and anchorage
independence of gastric cancer cells [22], implicating HIF-1a in
the pathogenesis of gastric cancer in the absence of hypoxia. We
now find that the capacitiy of HIF-1a to restrict ROS
production of gastric cancer cells also confers resistance to
chemotherapeutic agents that function via activation of p53
(Figure 6E). Interestingly, increasing effects on therapy resis-
tance via modulation of p53 and ROS have also been reported
for HIF-2a [49]. The HIF-a isoforms 1 and 2 show a wide
overlap in putative HIF targets and binding to hypoxic response
elements and definite allocation of hypoxia-induced effects to
either isoform is not always accomplishable [50]. Bertout et al.
demonstrated that inhibiting HIF-2a increases radiation-
induced apoptosis via ROS accumulation and subsequent
augmentation of p53 activity [49]. In addition, Roberts et al.
showed that resistance against chemotherapy is partially
mediated by HIF-2a-mediated suppression of p53 in renal cell
carcinoma cells [51]. Hence, the herewith reported observations
warrant investigations into the potential role of HIF-2a, a task
that is currently under way in our laboratory.
In view of the clinical need to identify response predictors for
available treatment options, our results could potentially direct
treatment decisions: on one hand, knowledge of HIF-1a
overexpression could direct a choice of drugs that largely act in
a p53-independent fashion. On the other hand, a particular
benefit may result from combining HIF-1-inhibitors and DNA
damaging agents (e.g. 5-FU) in cancers with functional p53.
Conversely, a reduced efficacy of HIF-1-inhibitors might be
anticipated for treatment of p53 defective tumors, an aspect that
may constitute a confounding factor in clinical trials of HIF-1a-
inhibiting treatment regimes.
Materials and Methods
Cell culture and chemicals
AGS (CRL-1739, ATCC, Rockville, Maryland, USA) and
MKN28 (JCRB Cell Bank, Tokyo, Japan) cells were grown as
monolayer cultures in standard medium. Generation of AGS and
MKN28 cells stably expressing either siRNA specifically targeting
HIF-1a (knockdown, ‘‘KD’’) or unspecific control siRNA
(scrambled, ‘‘SCR’’) was published previously [22]. 5-fluorouracil
Figure 4. Effects of 5-FU on MKN28 cells with mutant p53. (A) Cell numbers of MKN28 KD and SCR cells 24 h after treatment with 5-FU under
normoxic conditions. Data are shown as percent of untreated cells. Cells in G1 phase (B) and apoptotic cells (C) were quantitated from DNA
histograms of MKN28 KD and SCR cells treated for 48 h with 10 mg/ml 5-FU. (D) Immunoblot analysis of p53, p21 and pRb protein levels in MKN28 KD
and SCR cells treated with 10 mg/ml 5-FU for 6 and 24 h. Actin served as loading control.
doi:10.1371/journal.pone.0012038.g004
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(5-FU), cis-Diammineplatinum(II) dichloride (cisplatin) and the
superoxide anion inhibitors diphenyleneiodonium chloride (DPI)
and apocynin were purchased from Sigma-Aldrich (Germany) and
dissolved in DMSO. PRIMA-1 (for p53-reactivation and induction
of massive apoptosis) was obtained from Tocris Biosciences
(Ellisville, Missouri, USA) and dissolved in sterile water. Vehicle
control of the solvents was included in all experiments.
Cell proliferation assay
For determination of cell growth, 36104 cells were seeded in
triplicate into 24-well plates, allowed to attach for 16 h and then
treated as indicated under normoxic or hypoxic conditions. After
treatment, cells were trypsinized, and viable cells were counted
using a hemocytometer.
Determination of cell cycle distribution and apoptosis by
flow cytometry
Cell cycle distribution including the pre-G1 fraction was
determined from DNA histograms as described [52]. Apoptosis
was also quantitated from detection of active, cleaved caspase-3 by
flow cytometry using an Alexa FluorH 488-conjugated antibody
(Cell Signaling Technology, Danvers, Massachusetts, USA).
Quantification of senescence
Senescence-associated b-galactosidase activity was assessed in
cytospin preparations as described [53].
Immunoblot analysis
Whole cell lysates were prepared as previously described [52], then
resolved on a 10% sodium dodecyl sulfate-polyacrylamide gel and
transferred to nitrocellulose (Amersham Biosciences, Freiburg,
Germany). Blots were probed with antibodies against p53 and
CDK2 (Santa Cruz Biotechnology, Santa Cruz, California, USA),
p21 (Oncogene Research Products, Bad Soden, Germany), cyclin A
(Upstate, Temecula, California, USA), pRb (BD Pharmingen,
Heidelberg, Germany), MDM2 (Calbiochem, San Diego, California,
USA), p65 (Cell Signaling Technology) and actin (Sigma-Aldrich).
Secondary antibodies were conjugated to Horseradish Peroxidase
(Dianova, Hamburg, Germany) and peroxidase activity was
visualized using the Western Lightning Chemiluminescence Reagent
Plus (Perkin Elmer Life Sciences, Boston, Massachusetts, USA).
Quantitative real-time PCR analysis
For real-time PCR analysis, total cellular RNA was extracted
with Trizol reagent (Invitrogen, Karlsruhe, Germany). First strand
cDNA was synthesized with an oligo (dT) primer and a
SuperScriptTM First Strand Synthesis System (Invitrogen). Quan-
titative real-time PCR analysis was performed by using TaqMan
PCR Universal Mastermix (for b-actin) or SYBR GREEN PCR
Master Mix (for A20 and cIAP1; Applied Biosystems, Darmstadt,
Germany). Primer sequences are supplied in Table S1. To
normalize the amount of input RNA, PCR reactions were done
with probe and primers for b-actin.
Transient transfection and reporter luciferase assay
Transient transfections of AGS cells were carried out using
Effectene Transfection Reagent (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. For overexpression
studies, cells were seeded at 36104 cells/24-well and transfected
with 100 ng of pcDNA HIF-1a (kindly provided by Wanja
Bernhardt, Universita¨tsklinikum Erlangen, Erlangen, Germany) or
pcDNA p65 (kindly provided by Hiroyasu Nakano, Jutendo
University, Tokyo, Japan), respectively. For HRE or NF-kB
luciferase assay, 36104 cells/24-well were co-transfected with
100 ng of pHRE-Luc (a gift from Randall S. Johnson, UCSD, San
Diego, California, USA) or IgkB-Luc (a gift from Florian R.
Greten, Technische Universita¨t Mu¨nchen, Mu¨nchen, Germany),
and 30 ng of phRL-null (Promega, Mannheim, Germany).
Luciferase activity was measured with the Dual Luciferase
Reporter Assay System (Promega) as described [54]. To achieve
transient p53 suppression, AGS cells were transfected at 30%
confluence with 75 or 150 nmol/L si p53, (Silencer Select siRNA,
Applied Biosystems) and analyzed 48 h after transfection. A non-
specific siRNA (si scr, Eurogentec, Seraing, Belgium) was used as
control.
Electrophoretic mobility shift assay (EMSA)
Nuclear protein extracts were prepared as described [54].
EMSA was performed as previously described [55] using 8 mg
of nuclear protein and 100 fmol/L of the end-radiolabeled
22 bp double stranded NF-kB consensus oligonucelotide
(forward strand: 59-AGT TGA GGG GAC TTT CCC AGG
C-39; E3292, Promega). Samples were resolved by electropho-
resis on a non-denaturating 5% polyacrylamide gel. After
drying of the gel, complex formation was visualized by
autoradiography. For supershift experiments, an anti-p65
antibody was added (Santa Cruz Biotechnology) prior to the
radiolabeled probes.
Measurement of intracellular superoxide levels
Intracellular superoxide anion levels were estimated using the
fluorescent dye dihydroethidium (DHE), obtained from Sigma-
Aldrich. After 24 h cultivation, cells were trypsinized, harvested
by centrifugation, resuspended in PBS containing 10 mmol/L
DHE for 251 min at 37uC and thereafter washed with ice-cold
PBS. Dye oxidation was determined by flow cytometry with
excitation and emission settings of 488 and 585 nm, respective-
ly. The mean fluorescence intensity of at least 16105 cells was
analyzed and corrected for autofluorescence from unlabeled
cells.
Statistical analysis
Shown are means 6 SEM of at least three independent
experiments. Statistical analysis was performed by two-tailed
Student t test using Prism 4.0 software (GraphPad Software, San
Diego, California, USA). Differences were considered statistically
significant at P,0.05.
Figure 5. HIF-1a-mediated activation of NF-kB limits the toxicity of 5-FU. (A) Nuclear extracts of AGS KD and SCR cells were prepared at the
indicated time points after treatment with 10 mg/ml 5-FU or TNFa as a positive control, and DNA-binding activity for NF-kB was examined by EMSA.
For supershift experiments, nuclear extracts were incubated with an anti-p65 antibody. (B) Expression of NF-kB target genes cIAP1 and A20 mRNA in
total RNA extracts from AGS KD and AGS SCR cells 48 h after treatment with 10 mg/ml 5-FU. Data were expressed relative to mRNA levels in untreated
AGS SCR cells, set at 1.0 (*, P,0.05; **, P,0.01). (C) AGS KD cells were co-transfected with either pcDNA p65 or pcDNA 3.1 and treated with 5-FU 24 h
post transfection. Cell numbers were after another 24 h and are presented as percent of untreated control cells (***, P,0.001). (D) DNA binding
activity for NF-kB was examined by EMSA using nuclear extracts of MKN28 KD and SCR cells treated with 10 mg/ml 5-FU or TNFa for the indicated
times. Antibody inhibition was performed with an anti-p65 antibody.
doi:10.1371/journal.pone.0012038.g005
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Supporting Information
Figure S1 HIF-1a mediates resistance towards the chemother-
apeutic agent cisplatin in AGS cells. Proliferation of AGS KD and
SCR cells 48 h after treatment with increasing concentrations of
cisplatin under normoxic conditions (**, P,0.01). Values
represent the mean 6 SEM of triplicate determinations and cell
numbers are shown as percent of untreated cells.
Found at: doi:10.1371/journal.pone.0012038.s001 (1.81 MB TIF)
Figure S2 HIF-1a mediates resistance towards the chemother-
apeutic agent 5-FU under hypoxic conditions. Proliferation of
AGS KD and SCR cells 24 h after treatment with increasing
concentrations of 5-FU under hypoxic conditions (**, P,0.01;
***, P,0.001). Values represent the mean 6 SEM of triplicate
determinations and cell numbers are shown as percent of
untreated cells.
Found at: doi:10.1371/journal.pone.0012038.s002 (1.81 MB TIF)
Figure S3 Restoration of wild-type p53 by PRIMA-1 in
MKN28 cells with mutant p53. MKN28 KD and SCR cells were
pretreated with 30 mmol/L PRIMA-1 for 6 h and then exposed to
10 mg/ml 5-FU. Cell growth was determined 24 h after treatment
with 5-FU (**, P,0.01). Values represent the mean 6 SEM of
triplicate determinations and cell numbers are shown as percent of
untreated cells.
Found at: doi:10.1371/journal.pone.0012038.s003 (1.81 MB TIF)
Figure S4 Overexpression of NF-kB subunit p65 in AGS KD
cells. AGS KD cells were co-transfected with either pcDNA p65 or
pcDNA 3.1 plus IgkB-Luc and phRL-null as internal control.
Cells were harvested 48 h post transfection and NF-kB luciferase
activity, normalised for Renilla luciferase activity, was expressed
relative to control transfected cells (***, P,0.001). Bottom panel
shows immunoblot analysis of p65 and actin 48 h post
transfection.
Found at: doi:10.1371/journal.pone.0012038.s004 (1.72 MB TIF)
Figure S5 Analysis of superoxide anion levels in AGS cells after
5-FU treatment. AGS KD and SCR cells were treated for 24 h
with 10 mg/ml 5-FU under normoxia, stained with 10 mmol/L
dihydroethidium, and dye oxidation was determined by flow
cytometry. Values represent the mean 6 SEM of three
independent experiments (**, P,0.01).
Found at: doi:10.1371/journal.pone.0012038.s005 (1.77 MB TIF)
Table S1 List of primer and probe sequences.
Found at: doi:10.1371/journal.pone.0012038.s006 (1.77 MB TIF)
Author Contributions
Conceived and designed the experiments: NR KD CS TC. Performed the
experiments: NR CD AH. Analyzed the data: NR CD KD CS TC.
Contributed reagents/materials/analysis tools: BW KD. Wrote the paper:
NR TC. Critical revision of the paper: TC CD BW KD CS. Study
supervision: TC.
References
1. Gatti L, Zunino F (2005) Overview of tumor cell chemoresistance mechanisms.
Methods Mol Med 111: 127–148.
2. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med
53: 615–627.
3. Morin PJ (2003) Drug resistance and the microenvironment: nature and nurture.
Drug Resist Updat 6: 169–172.
4. Chabner BA, Roberts TG (2005) Chemotherapy and the war on cancer. Nat
Rev Cancer 5: 65–72.
5. Wilson TR, Longley DB, Johnston PG (2006) Chemoresistance in solid tumours.
Ann Oncol 17: 315–324.
6. Brown LM, Cowen RL, Debray C, Eustace A, Erler JT, et al. (2006) Reversing
Hypoxic Cell Chemoresistance in Vitro Using Genetic and Small Molecule
Approaches Targeting Hypoxia Inducible Factor-1. Mol Pharmacol 69: 411–418.
7. Sullivan R, Pare GC, Frederiksen LJ, Semenza GL, Graham CH (2008)
Hypoxia-induced resistance to anticancer drugs is associated with decreased
senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther 7:
1961–1973.
8. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, et al. (2003) The
hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy.
Oncogene 22: 3213–3220.
9. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:
721–732.
10. Frede S, Berchner-Pfannschmidt U, Fandrey J (2007) Regulation of hypoxia-
inducible factors during inflammation. Methods Enzymol 435: 405–419.
11. Weidemann A, Johnson RS (2008) Biology of HIF-1[alpha]. Cell Death Differ
15: 621–627.
12. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, et al. (2000)
Overexpression of hypoxia-inducible factor 1alpha is a marker for an
unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60:
4693–4696.
13. Bos R, van der GP, Greijer AE, Shvarts A, Meijer S, et al. (2003) Levels of
hypoxia-inducible factor-1alpha independently predict prognosis in patients with
lymph node negative breast carcinoma. Cancer 97: 1573–1581.
14. Kurokawa T, Miyamoto M, Kato K, Cho Y, Kawarada Y, et al. (2003)
Overexpression of hypoxia-inducible-factor 1alpha(HIF-1alpha) in oesophageal
squamous cell carcinoma correlates with lymph node metastasis and pathologic
stage. Br J Cancer 89: 1042–1047.
15. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, et al. (1999)
Overexpression of hypoxia-inducible factor 1alpha in common human cancers
and their metastases. Cancer Res 59: 5830–5835.
16. Patiar S, Harris AL (2006) Role of hypoxia-inducible factor-1alpha as a cancer
therapy target. Endocr Relat Cancer 13: 61–75.
17. Hao J, Song X, Song B, Liu Y, Wei L, et al. (2008) Effects of lentivirus-mediated
HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their
dependence on p53 status in fibrosarcoma cells. Cancer Gene Ther 15: 449–455.
18. Liu L, Ning X, Sun L, Zhang H, Shi Y, et al. (2008) Hypoxia-inducible factor-1
alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer
Sci 99: 121–128.
19. Nardinocchi L, Puca R, Sacchi A, D’Orazi G (2009) Inhibition of HIF-1alpha
activity by homeodomain-interacting protein kinase-2 correlates with sensitiza-
tion of chemoresistant cells to undergo apoptosis. Mol Cancer 8: 1.
20. Sasabe E, Zhou X, Li D, Oku N, Yamamoto T, et al. (2007) The involvement of
hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemo-
therapeutic drugs of oral squamous cell carcinoma cells. Int J Cancer 120: 268–277.
21. Liu L, Ning X, Sun L, Shi Y, Han S, et al. (2007) Involvement of MGr1-Ag/
37LRP in the vincristine-induced HIF-1 expression in gastric cancer cells. Mol
Cell Biochem 303: 151–160.
22. Rohwer N, Welzel M, Daskalow K, Pfander D, Wiedenmann B, et al. (2008)
Hypoxia-inducible factor 1alpha mediates anoikis resistance via suppression of
alpha5 integrin. Cancer Res 68: 10113–10120.
Figure 6. ROS as molecular mediator of the HIF-1a effect on chemosensitivity in AGS KD cells. (A–D) AGS KD cells were pretreated for
16 h with different concentrations of the NADPH oxidase inhibitors diphenyleneiodonium (DPI) or apocynin. Proliferation of DPI-pretreated (A) or
apocynin-pretreated (B) AGS KD cells 24 h after treatment with 10 mg/ml 5-FU under normoxic conditions (***, P,0.001). Cell numbers are shown as
percent of untreated cells. (C and D) The effect of DPI (C) and apocynin (D) on p53 and p21 protein levels was determined by immunoblot analysis
using whole cell extracts of AGS KD cells treated for 24 h with 10 mg/ml 5-FU. (E) Proposed model for HIF-1-dependent regulation of chemosensitivity
by ROS-induced modulation of p53. (left panel) Chemotherapy-induced response in HIF-1-competent cells. HIF-1 counteracts generation of ROS at
the mitochondrial level. Decreased ROS levels in turn abate activation of p53 and allow for cell cycle progression despite chemotherapy. Hence, HIF-
1-competent cells display a more chemoresistant phenotype. Ub, ubiquitin; P, phosphate. (right panel) Chemotherapy-induced response in HIF-1-
deficient cells. Inactivation of HIF-1 leads to accelerated mitochondrial ROS generation. ROS are potent inducers of p53 and thus boost activation of
p53 by chemotherapeutic agents. P53 in turn transactivates -among others - the cyclin-dependent kinase (CDK) inhibitor p21 and inhibits NF-kB
activity. The combined activation of p53 and inhibition of NF-kB, result in apoptosis and/or senescence of HIF-1-deficient cells, hence a more
chemosensitive phenotype.
doi:10.1371/journal.pone.0012038.g006
HIF-1a and Chemosensitivity
PLoS ONE | www.plosone.org 12 August 2010 | Volume 5 | Issue 8 | e12038
23. Schmitt CA (2003) Senescence, apoptosis and therapy-cutting the lifelines of
cancer. Nat Rev Cancer 3: 286–295.
24. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, et al. (2002)
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-
weight compound. Nat Med 8: 282–288.
25. Cusack JC, Jr., Liu R, Baldwin AS, Jr. (2000) Inducible Chemoresistance to 7-
Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) in
Colorectal Cancer Cells and a Xenograft Model Is Overcome by Inhibition of
Nuclear Factor-{kappa}B Activation. Cancer Res 60: 2323–2330.
26. Cusack JC, Jr., Liu R, Houston M, Abendroth K, Elliott PJ, et al. (2001)
Enhanced Chemosensitivity to CPT-11 with Proteasome Inhibitor PS-341::
Implications for Systemic Nuclear Factor-{{kappa}}B Inhibition. Cancer Res
61: 3535–3540.
27. Wang CY, Cusack JC, Jr., Liu R, Baldwin AS, Jr. (1999) Control of inducible
chemoresistance: enhanced anti-tumor therapy through increased apoptosis by
inhibition of NF-kappaB. Nat Med 5: 412–417.
28. Martindale JL, Holbrook NJ (2002) Cellular response to oxidative stress:
signaling for suicide and survival. J Cell Physiol 192: 1–15.
29. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, et al. (2007) HIF-1
inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal
cell carcinoma by repression of C-MYC activity. Cancer Cell 11: 407–420.
30. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, et al. (2008)
Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to
hypoxia. J Biol Chem 283: 10892–10903.
31. Nakamura J, Kitajima Y, Kai K, Mitsuno M, Ide T, et al. (2009) Hypoxia-
inducible factor-1alpha expression predicts the response to 5-fluorouracil-based
adjuvant chemotherapy in advanced gastric cancer. Oncol Rep 22: 693–699.
32. Welford SM, Bedogni B, Gradin K, Poellinger L, Broome PM, et al. (2006)
HIF1alpha delays premature senescence through the activation of MIF. Genes
Dev 20: 3366–3371.
33. Harris SL, Levine AJ (2005) The p53 pathway: positive and negative feedback
loops. Oncogene 24: 2899–2908.
34. Vazquez A, Bond EE, Levine AJ, Bond GL (2008) The genetics of the p53
pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7: 979–987.
35. Hammond EM, Giaccia AJ (2006) Hypoxia-inducible factor-1 and p53: friends,
acquaintances, or strangers? Clin Cancer Res 12: 5007–5009.
36. Wirthner R, Wrann S, Balamurugan K, Wenger RH, Stiehl DP (2008) Impaired
DNA double-strand break repair contributes to chemoresistance in HIF-1 alpha-
deficient mouse embryonic fibroblasts. Carcinogenesis 29: 2306–2316.
37. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, et al. (2003) Hypoxia-
inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell
Biol 23: 359–369.
38. Ravi R, Mookerjee B, van HY, Bedi GC, Giordano A, et al. (1998) p53-
mediated repression of nuclear factor-kappaB RelA via the transcriptional
integrator p300. Cancer Res 58: 4531–4536.
39. Culmsee C, Siewe J, Junker V, Retiounskaia M, Schwarz S, et al. (2003)
Reciprocal inhibition of p53 and nuclear factor-kappaB transcriptional activities
determines cell survival or death in neurons. J Neurosci 23: 8586–8595.
40. Nakanishi C, Toi M (2005) Nuclear factor-kappaB inhibitors as sensitizers to
anticancer drugs. Nat Rev Cancer 5: 297–309.
41. Belaiba RS, Bonello S, Zahringer C, Schmidt S, Hess J, et al. (2007) Hypoxia
up-regulates hypoxia-inducible factor-1alpha transcription by involving phos-
phatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth
muscle cells. Mol Biol Cell 18: 4691–4697.
42. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, et al. (2008)
NF-kappaB links innate immunity to the hypoxic response through transcrip-
tional regulation of HIF-1alpha. Nature 453: 807–811.
43. Walmsley SR, Print C, Farahi N, Peyssonnaux C, Johnson RS, et al. (2005)
Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-
kappaB activity. J Exp Med 201: 105–115.
44. Karin M (2006) Nuclear factor-kappaB in cancer development and progression.
Nature 441: 431–436.
45. Holley AK, St Clair DK (2009) Watching the watcher: regulation of p53 by
mitochondria. Future Oncol 5: 117–130.
46. Liu Y, Fiskum G, Schubert D (2002) Generation of reactive oxygen species by
the mitochondrial electron transport chain. J Neurochem 80: 780–787.
47. Kim JW, Tchernyshyov I, Semenza GL, Dang CV (2006) HIF-1-mediated
expression of pyruvate dehydrogenase kinase: a metabolic switch required for
cellular adaptation to hypoxia. Cell Metab 3: 177–185.
48. Archer SL, Gomberg-Maitland M, Maitland ML, Rich S, Garcia JG, et al.
(2008) Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-
ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary
hypertension and cancer. Am J Physiol Heart Circ Physiol 294: H570–H578.
49. Bertout JA, Majmundar AJ, Gordan JD, Lam JC, Ditsworth D, et al. (2009)
HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and
radiation responses. Proc Natl Acad Sci U S A 106: 14391–14396.
50. Tormos KV, Chandel NS (2010) Inter-connection between mitochondria and
HIFs. J Cell Mol Med 14: 795–804.
51. Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, et al. (2009)
Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2
and reverses chemoresistance of renal carcinoma cells. Cancer Res 69:
9056–9064.
52. Plath T, Detjen K, Welzel M, von MZ, Murphy D, et al. (2000) A novel function
for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of
the alpha(5)beta(1) fibronectin receptor. J Cell Biol 150: 1467–1478.
53. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, et al. (2002) A senescence
program controlled by p53 and p16INK4a contributes to the outcome of cancer
therapy. Cell 109: 335–346.
54. Cramer T, Juttner S, Plath T, Mergler S, Seufferlein T, et al. (2008) Gastrin
transactivates the chromogranin A gene through MEK-1/ERK- and PKC-
dependent phosphorylation of Sp1 and CREB. Cell Signal 20: 60–72.
55. Dame C, Sola MC, Lim KC, Leach KM, Fandrey J, et al. (2004) Hepatic
erythropoietin gene regulation by GATA-4. J Biol Chem 279: 2955–2961.
HIF-1a and Chemosensitivity
PLoS ONE | www.plosone.org 13 August 2010 | Volume 5 | Issue 8 | e12038
